Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effektivitet og sikkerhed af Teplizumab hos japanske deltagere med fase 2 type 1 -diabetes (KIBOU-T1D)

6. november 2026 opdateret af: Sanofi

Effekt og sikkerhed af Teplizumab i behandlingen af ​​japanske pædiatriske og voksne deltagere i alderen 8 til 34 år med trin 2 type 1-diabetes: Et multicenter, randomiseret, åbent, kontrolleret studie.

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.

Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA.

Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Total study duration is approximately 756 days.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

5

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Fukuoka, Japan, 812-0025
        • Investigational Site Number : 3920017
      • Kyoto, Japan, 606-8507
        • Investigational Site Number : 3920016
      • Nagasaki, Japan, 852-8501
        • Investigational Site Number : 3920014
      • Osaka, Japan, 545-8586
        • Investigational Site Number : 3920004
      • Tokyo, Japan, 101-8309
        • Investigational Site Number : 3920020
      • Tokyo, Japan, 162-8666
        • Investigational Site Number : 3920003
    • Chiba
      • Ichikawa, Chiba, Japan, 272-0827
        • Investigational Site Number : 3920015
    • Gunma
      • Maebashi, Gunma, Japan, 371-8511
        • Investigational Site Number : 3920011
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8543
        • Investigational Site Number : 3920006
    • Hyōgo
      • Kobe, Hyōgo, Japan, 650-0017
        • Investigational Site Number : 3920018
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Japan, 920-8641
        • Investigational Site Number : 3920009
    • Iwate
      • Yahaba, Iwate, Japan, 028-3695
        • Investigational Site Number : 3920007
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 222-0036
        • Investigational Site Number : 3920019
    • Saitama
      • Iruma, Saitama, Japan, 350-0495
        • Investigational Site Number : 3920001
    • Yamanashi
      • Chūō, Yamanashi, Japan, 409-3898
        • Investigational Site Number : 3920010

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 34 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female Japanese participant, 1 (inclusive) to 34 years (inclusive) of age, at the time of signing the informed consent. Japanese: born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan.
  • Confirmed diagnosis of Stage 2 T1D based on following criteria:
  • Participant is positive for 2 or more T1D related auto-antibodies (confirmed by written medical history and/or obtained at study screening). The autoantibodies that are to be confirmed are anti-GAD (glutamic acid decarboxylase), anti-IA2 (insulinoma-associated antigen 2), anti-insulin, anti-ZnT8 (zinc transporter 8), and/or ICA (islet cell antibody).
  • Oral glucose tolerance test (OGTT) or blood HbA1c confirms the participant has dysglycemia without overt hyperglycemia.
  • Participant must be in good health (except for being Stage 2 T1D) as determined by medical e)valuation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) XE " ECG " \f Abbreviation \t "electrocardiogram" .
  • Participant is up to date with routine age-appropriate immunizations according to current local specific guideline prior to randomization.
  • Female participants should use contraceptives consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is considered fertile (woman of childbearing potential - WOCBP) from the time of menarche until becoming postmenopausal unless permanently sterile. Female participants are eligible to participate if one of the following conditions applies:
  • Is a woman of nonchildbearing potential (WONCBP) OR
  • Is a WOCBP and agrees to keep abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or use other highly effective contraceptive method, from signing of the informed consent to at least 3 months and 2 weeks after randomization and agrees not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction during this period.

A WOCBP must have at least a negative highly sensitive pregnancy test within 48 hours before the administration of study intervention.

If a urine test cannot be confirmed as negative (eg, an ambiguous result), a blood pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Participants are excluded from the study if any of the following criteria apply:

  • Any presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic (except Stage 2 T1D), hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Participant has clinical signs and symptoms consistent with COVID19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
  • For participant ≥18 years, blood donation of 400 mL within 12 weeks (male) or 16 weeks (female), 200 mL within 4 weeks or apheresis donation within 2 weeks before randomization; for participant <18 years, blood donation of any volume within 16 weeks before randomization; for any participant, blood transfusion (any volume) within 2 months before randomization.
  • Presence or history of drug hypersensitivity to any biologic medication, or clinically significant allergic disease as diagnosed and treated by a physician. Participants with known hypersensitivity to teplizumab or components of the teplizumab injection (including sodium phosphate, sodium chloride, polysorbate 80).
  • Participants with a history of active or latent or inactive tuberculosis (TB), including chest X-ray consistent with TB, regardless of treatment, or have a positive QuantiFERON-TB Gold test or T-SPOT TB test at screening.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein Barr virus (EBV), or history of infectious mononucleosis within 3 months before enrollment.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with cytomegalovirus (CMV).
  • Participants with a history of invasive opportunistic infections, such as histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis, irrespective of resolution.
  • Participants have other autoimmune diseases, except clinically stable autoimmune thyroid disease, or celiac disease.
  • Participants with a history of malignancy occurring within 5 years before randomization (except successfully treated carcinoma in situ of the cervix, or adequately treated nonmetastatic squamous cell or basal cell carcinoma of the skin).
  • Participants with fever (temperature ≥38.0°C) within 48 hours before randomization; or with chronic persistent or recurring infection(s) requiring active treatment with antibiotics, antiviral or antifungals within 4 weeks before randomization; or with other frequent recurrent infections deemed unacceptable as per Investigator's judgement.
  • If female, pregnancy (defined as positive blood or urine pregnancy test) or breast-feeding.
  • Participant has recent or planned vaccinations as follows:
  • Live vaccines: within 8 weeks before randomization, and/or within 54 weeks after randomization.
  • Non-live vaccines: any initial non-live vaccination within 2 weeks before randomization, and/or within 8 weeks after randomization.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including high dose, inhaled, extensive topical, or systemic glucocorticoids.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to significantly influence glucose tolerance (anti-hyperglycemic agents, atypical antipsychotics, diphenylhydantoin, niacin etc.).
  • Participant has received any anti-CD3 (cluster of differentiation 3) antibody treatment (including teplizumab) before randomization.
  • Participant who has received any biologic therapy within five half-lives of the therapy or within 6 months before randomization whichever is longer, or plan to receive any biologic therapy within 6 weeks after randomization.
  • Any participant enrolled or having participated, in this or any other clinical study involving an investigational medicinal product (IMP) or in any other type of medical research and is still in the exclusion period according to applicable regulations (eg, having received an IMP of new active pharmaceutical ingredient (API) within 4 months or that of an approved API within 3 months before the administration of this study's IMP).
  • Participant has any of the following hematologic parameters before randomization:
  • Lymphocyte count <1.0 ×109/L.
  • Neutrophil count <1.5 ×109/L.
  • Platelet count <150 ×109/L.
  • Hemoglobin <100 g/L.
  • Participant has any of the following liver function test abnormalities before randomization:
  • AST >2 × ULN (upper limit normal).
  • ALT >2 × ULN.
  • Total bilirubin >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia.
  • Positive result on any of the following tests:
  • Hepatitis B surface antigen or hepatitis B core antibody confirmed by positive HBV-DNA (hepatitis B virus DNA).
  • Anti-hepatitis C virus antibody confirmed by positive HCV-RNA (hepatitis C virus RNA).
  • Human immunodeficiency virus antigen/ antibodies.
  • Positive SARS-CoV-2 test.
  • Participant who has contraindications or known allergy to both nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, or anti-histamines and in the opinion of the Investigator, cannot participate in the study.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Teplizumab

Participants will receive Teplizumab via IV infusion

Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion

Andre navne:
  • SAR446681
  • TZIELD
Ingen indgriben: Control

Participants will receive no treatment in the control group

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antal deltagere med trin 3 type 1 diabetes baseret på American Diabetes Association kriterier
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104
Skift fra baseline i området under kurven (AUC) af C-peptid
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104
Change from baseline in AUC of endogenous insulin
Tidsramme: From baseline up to Week 104
From baseline up to Week 104
Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory test
Tidsramme: Throughout the study, approximately 756 days

TEAE: treatment-emerged adverse event; SAE: serious adverse event; AE: adverse event

Throughout the study, approximately 756 days

Sekundære resultatmål

Resultatmål
Tidsramme
Ændring fra baseline i fastende plasmaglukose (FPG) fra en oral glucosetolerancetest
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104
Skift fra baseline i 2-timers plasmaglukose fra en oral glukosetolerance-test
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104
Skift fra baseline af hæmoglobin A1C (HBA1C)
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104
Serumkoncentration af teplizumab
Tidsramme: Fra dag 1 til dag 28
Fra dag 1 til dag 28
Antal deltagere med anti-narkotika antistoffer
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104
Antal deltagere med neutraliserende antistoffer
Tidsramme: Fra baseline op til uge 104
Fra baseline op til uge 104

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. juli 2025

Primær færdiggørelse (Anslået)

6. marts 2028

Studieafslutning (Anslået)

6. marts 2028

Datoer for studieregistrering

Først indsendt

20. januar 2025

Først indsendt, der opfyldte QC-kriterier

20. januar 2025

Først opslået (Faktiske)

24. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ACT18487
  • U1111-1308-1324 (Registry Identifier: ICTRP)
  • jRCT2031240637 (Registry Identifier: JRCT)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .